Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

BACKGROUND: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stro...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Am Heart Assoc
Hlavní autoři: Magnani, Giulia, Bonaca, Marc P., Braunwald, Eugene, Dalby, Anthony J., Fox, Keith A. A., Murphy, Sabina A., Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Morrow, David A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://ncbi.nlm.nih.gov/pubmed/25792124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001505
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky